Can-Fite BioPharma (CANF)

• Market cap: $9.02M
• 1 day: 2.78%
• 5 days: -4.52%
• 1 month: -26.37%
• 3 months: -25.25%
• 6 months: -45.39%
• Year to date: -28.50%
• 1 year: -28.85%
• 5 years: -94.84%
• 10 years: -99.73%

About: Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Employees: 5

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

9% more funds holding

Funds holding: 11 [Q2] → 12 (+1) [Q3]

0.01% less ownership

Funds ownership: 0.04% [Q2] → 0.04% (-0.01%) [Q3]

15% less capital invested

Capital invested by funds: $1.79M [Q2] → $1.52M (-$278K) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10 576% upside
• Avg. target: $12.67 756% upside
• High target: $18 1,116% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 25% 1-year accuracy 38 / 150 met price target	576% upside $10	Buy Maintained	5 Dec 2024
HC Wainwright & Co. Vernon Bernardino 32% 1-year accuracy 19 / 59 met price target	1,116% upside $18	Buy Reiterated	12 Nov 2024
EF Hutton Jason Kolbert 25% 1-year accuracy 38 / 150 met price target	576% upside $10	Buy Maintained	10 Oct 2024